EP0647134A4 - Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin. - Google Patents

Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin.

Info

Publication number
EP0647134A4
EP0647134A4 EP93915448A EP93915448A EP0647134A4 EP 0647134 A4 EP0647134 A4 EP 0647134A4 EP 93915448 A EP93915448 A EP 93915448A EP 93915448 A EP93915448 A EP 93915448A EP 0647134 A4 EP0647134 A4 EP 0647134A4
Authority
EP
European Patent Office
Prior art keywords
sibutramine
disorders
compositions
methods
optically pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93915448A
Other languages
English (en)
French (fr)
Other versions
EP0647134A1 (de
Inventor
James W Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of EP0647134A1 publication Critical patent/EP0647134A1/de
Publication of EP0647134A4 publication Critical patent/EP0647134A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP93915448A 1992-06-23 1993-06-22 Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin. Withdrawn EP0647134A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90304092A 1992-06-23 1992-06-23
US903040 1992-06-23
PCT/US1993/005966 WO1994000114A1 (en) 1992-06-23 1993-06-22 Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine

Publications (2)

Publication Number Publication Date
EP0647134A1 EP0647134A1 (de) 1995-04-12
EP0647134A4 true EP0647134A4 (de) 1997-07-30

Family

ID=25416838

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93915448A Withdrawn EP0647134A4 (de) 1992-06-23 1993-06-22 Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin.

Country Status (5)

Country Link
EP (1) EP0647134A4 (de)
JP (1) JPH08500093A (de)
AU (1) AU4542893A (de)
CA (1) CA2138998A1 (de)
WO (1) WO1994000114A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
GB9402641D0 (en) * 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
US5676967A (en) * 1995-04-18 1997-10-14 Brennen Medical, Inc. Mesh matrix wound dressing
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
EP1169027A4 (de) * 1999-03-19 2004-10-20 Abbott Gmbh & Co Kg Arthrosebehandlung
DK1466889T3 (da) 1999-04-06 2008-09-08 Sepracor Inc O-Desmethylvenlafaxin-succinat
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
ATE369330T1 (de) 2001-02-12 2007-08-15 Wyeth Corp O-desmethyl-venlafaxine succinat salz
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
MXPA05000566A (es) * 2002-07-24 2005-08-29 Cypress Bioscience Inc Tratamiento de depresion secundaria al dolor (dsp).

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008993A1 (de) * 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9400114A1 *

Also Published As

Publication number Publication date
EP0647134A1 (de) 1995-04-12
AU4542893A (en) 1994-01-24
JPH08500093A (ja) 1996-01-09
WO1994000114A1 (en) 1994-01-06
CA2138998A1 (en) 1994-01-06

Similar Documents

Publication Publication Date Title
EP0647134A4 (de) Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin.
PL324313A1 (en) 10-axcyloxy 10,11-dihydrobenz/b,f/azepin-5-carboxyamides useful in treating nervous system disorders
EP0695123A4 (de) Verfahren und zusammensetzungen zur behandlung gastrischer störungen unter verwendung optisch reinen pantoprazols
AU2287495A (en) Methods and compositions for treating depression and other disorders using optically pure s(+) fluoxetine
HUP0001237A3 (en) Methods for treating vascular disorders
PH30791A (en) Fibre treatment method.
EP0611302A4 (de) Verfahren und zusammensetzungen zur behandlung von allergischen reaktionen.
EP0708639A4 (de) Verfahern und zusammensetzungen zur behandlumng von depression und anderen erkrankungen unter verwendung von optisch-reienem sibuttramin
AP9600782A0 (en) Recombinant il,4 antibodies useful in treatment of il,4 mediated disorders
EP0589373A3 (de) Verfahren zur Steigerung von Haarglanz und Reparierung von alkalischen Schädigungen des Haares.
HUP0003488A3 (en) Methods and compsitions for treating pulmonary disorders using optically pure (s)-salmeterol
KR970000398B1 (en) Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethan and pentafluorethane
GB2229889B (en) Videodisc and videodisc player,and vision mixing simulator using the same
EP0700292A4 (de) Verfahren und zusammensetzungen zur behandlung von magenerkrankungen unter verwendung von optisch reinem (+)-pantoprazol
EP0711159A4 (de) Verfahren und zusammensetzungen zur behandlung von asthma, arthereosklerose und entzuendlichen erkrankungen unter verwendung von optisch reinem (-)-zilenton
EP0671500A3 (de) Zusammensetzungen für die Behandlung von Textilien.
ZA942809B (en) Treatment
EP0708638A4 (de) Verfahren und zusammensetzungen zur behandlung von depression und anderen psychiatischen krankheiten
AU4529897A (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
AU696392B2 (en) Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
AU3275993A (en) Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
EP0661971A4 (de) Verfahren und zusammensetzungen zur behandlung von hypertonie, angina und anderen erkrankungen unter verwendung von optisch reinem s(-) felodipin.
EP0663822A4 (de) Verfahren und zusammensetzungen zur behandlung von hypertonie, angina und anderen erkrankungen unter verwendung von optisch reinem s(-) nitrendipin.
GB9616870D0 (en) Methods and compositions for treating depression and other disorders
HU9401579D0 (en) Methods for administering biological agents and microparticle compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970612

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19991118

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEPRACOR INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050101